Business Wire

Veristat Launches Strategic Resourcing to Build Greater Flexibility in its Suite of Engagement Models

Share

Veristat, a scientific-minded global clinical research organization (CRO), announced today the formalization of its Strategic Resourcing solution to offer clients the delivery of clinical development and regulatory expertise options fully tailored to their needs. Clients now have access to difficult-to-find experts dedicated to a specific requirement or function to meet their objectives and timelines.

Veristat has been providing demand-based resourcing on a less formalized basis for many years. With the Strategic Resourcing solution, a pipeline of discipline-specific expertise is available and ready to seamlessly integrate into dynamic clinical environments. Veristat resources support work across many disciplines including biostatistics, programming and data management, regulatory consulting, clinical operations including clinical monitoring, project management, site management, as well as medical affairs/safety, medical/regulatory writing, and pharmacovigilance.

“The biopharmaceutical industry is innovating and developing new treatments so rapidly that resourcing demands now outpace the current available talent pool,” commented Patrick Flanagan, Chief Executive Officer at Veristat. “This was a top industry challenge prior to the COVID-19 pandemic, and it remains a top challenge today. Sponsors expect their external partners to continually improve upon the ways in which they can help them achieve true scientific progress delivered with process agility. Our strategic resourcing option provides the necessary flexibility to support a client project in the manner they determine is best.”

Leading the initiative is Bill Donovan, Senior Vice President, Strategic Solutions at Veristat. An industry veteran, Bill has 20+ years of leadership experience partnering with global pharmaceutical and biotechnology companies to accelerate time-to-market results across all stages of clinical trials. Delivering quality specialty resourcing to meet a sponsor’s full spectrum of needs has been a vital component of customer engagements led by Donovan.

“Refining the ways in which we partner with clients to deliver higher efficiencies with accelerated timelines is an ongoing focus for us,” commented Donovan. “Providing drug developers with an agile and specialized resourcing model fully supports this objective. I am thrilled that Veristat has formalized our ability to enhance customer value by allowing sponsors to hire our experts when they cannot find the right talent to support study success.”

Veristat is currently working on projects to treat cancers, rare diseases, neurological disorders, infectious diseases and more. Treatments span vaccines, gene therapies, complex generics, immuno-therapies, and novel drugs. For many clients, Veristat becomes a sponsor’s project team. For others, Veristat provides the medical, scientific, clinical, and statistical expertise to help sponsors advance their therapy into and through the clinical development and regulatory approval process.

Veristat continues to offer its core end-to-end capabilities across the development continuum in both full service and functional service support capabilities as well. Learn more about Veristat’s Strategic Resourcing Solutions here: https://www.veristat.com/services/strategic-resourcing

About Veristat

Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 27 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last 10 years.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. Our bold thinking, focus, and extensive experience supporting complex drug development in rare and ultra-rare diseases significantly impacted the approval of 12% of the 2021 U.S. Food and Drug Administration (FDA) novel drugs.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Veristat:
Lauren L. Brennan, VP of Marketing
media@veristat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SCENTMATIC's AI "KAORIUM" Debuts at THAMEEN Fragrance Launch in London's Selfridges4.7.2025 12:13:00 EEST | Press release

SCENTMATIC Inc., a leader in scent digitalization, introduced its AI-powered scent-to-language system, KAORIUM, at the THAMEEN Fragrance new product launch event. This pivotal event took place from June 5 to 11, 2025, at Selfridges department store in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703662207/en/ State of exhibition Global Expansion: KAORIUM Establishes UK Presence Europe leads the global fragrance market, with the UK projected to reach US$2.82 billion by 2033. Recognizing this, SCENTMATIC is rapidly expanding its international footprint. In May 2024, SCENTMATIC established its overseas subsidiary, KAORIUM, in London, appointing industry expert Ben Yanoushek as CEO. Official UK operations commenced on February 1, 2025, with the launch of its dedicated website: www.kaorium.com. KAORIUM Trialed at "Florentine Diamond" Launch Event The "Florentine Diamond" launch event for luxury brand THAMEEN Frag

Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 02:00:00 EEST | Press release

The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster than the global economy, generating significant commercial opportunities as long as the mounting challenges of climate change, labour shortages and infrastructure gaps are addressed. Inbound and outbound trips increasing fast Asia is on track to become the world’s fastest-growing tourism economy, with the direct travel and tourism GDP contribution expected to exceed 7% across the region by 2034. Notably, India and China

The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 22:00:00 EEST | Press release

The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate

Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 15:59:00 EEST | Press release

Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac

Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 15:05:00 EEST | Press release

In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye